Related Experiment Video

Updated: Aug 7, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

CF-Emerging therapies: Modulation inflammation

M Fayon1,

  • 1C.R.C.M. pédiatrique & Centre de Recherche (CEDRE), CHU de Bordeaux-Université Victor Segalen Bordeaux 2, Laboratoire de Physiologie Cellulaire Respiratoire, Place Amélie Raba Léon, 33076 Bordeaux Cedex, France. michael.fayon@chu-bordeaux.fr

Paediatric Respiratory Reviews
|June 27, 2006
PubMed

Insights

Persistent inflammation drives cystic fibrosis (CF) lung disease. Early intervention with agents like macrolides may offer benefits, but further research is needed for other treatments.

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Persistent and dysregulated inflammation is a key factor in cystic fibrosis (CF) lung disease progression.
  • Neutrophil accumulation in airways is a hallmark of advancing CF lung disease.

Purpose of the Study:

  • To review current understanding of CF airway inflammation.
  • To evaluate potential therapeutic agents for modulating inflammation in CF.

Main Methods:

  • Literature review of inflammatory processes in CF.
  • Analysis of existing and potential therapeutic strategies for CF lung disease.

Main Results:

  • Macrolides show promise as anti-inflammatory agents with a good safety profile for long-term use in CF.
  • Steroids are generally not recommended for CF, except in specific circumstances.
  • Leukotriene modifiers, N-acetylcysteine, anti-elastase, and anti-cytokines require further investigation.

Conclusions:

  • Early treatment of CF lung disease, before significant lung damage occurs, is crucial.
  • Targeting airway inflammation is a critical therapeutic goal in CF management.

More Related Videos

Increased Recovery Time and Decreased LPS Administration to Study the Vagus Nerve Stimulation Mechanisms in Limited Inflammatory Responses06:43

Increased Recovery Time and Decreased LPS Administration to Study the Vagus Nerve Stimulation Mechanisms in Limited Inflammatory Responses

Published on: March 29, 2017

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...